Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR 82.60
+0.10 (0.12%)
Mar 31, 2025, 1:50 PM CET
Merck & Co. Revenue
In the year 2024, Merck & Co. had annual revenue of $64.17B USD with 6.74% growth. Merck & Co. had revenue of $15.62B in the quarter ending December 31, 2024, with 6.79% growth.
Revenue
$64.17B
Revenue Growth
+6.74%
P/S Ratio
n/a
Revenue / Employee
$855.57K
Employees
75,000
Market Cap
208.09B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
Merck & Co. News
- 2 hours ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK - Accesswire
- 2 hours ago - MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - Accesswire
- 4 hours ago - Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - PRNewsWire
- 21 hours ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK - Accesswire
- 21 hours ago - ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - Accesswire
- 1 day ago - Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - Seeking Alpha
- 1 day ago - Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK - Accesswire
- 1 day ago - ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - GlobeNewsWire